Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

Neurocrine Biosciences, Inc. (NBIX): $98.24

0.84 (+0.86%)

POWR Rating

Component Grades














  • Quality is the dimension where NBIX ranks best; there it ranks ahead of 85.61% of US stocks.
  • The strongest trend for NBIX is in Stability, which has been heading down over the past 179 days.
  • NBIX's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

NBIX Stock Summary

  • NBIX's current price/earnings ratio is 98.71, which is higher than 93.33% of US stocks with positive earnings.
  • The price/operating cash flow metric for Neurocrine Biosciences Inc is higher than 84.07% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 7.8, Neurocrine Biosciences Inc has a higher such ratio than 81.42% of stocks in our set.
  • Stocks that are quantitatively similar to NBIX, based on their financial statements, market capitalization, and price volatility, are DLB, CHKP, RVNC, AXTI, and MITK.
  • NBIX's SEC filings can be seen here. And to visit Neurocrine Biosciences Inc's official web site, go to

NBIX Valuation Summary

  • NBIX's price/sales ratio is 8.7; this is 128.95% higher than that of the median Healthcare stock.
  • Over the past 243 months, NBIX's EV/EBIT ratio has gone up 115.2.
  • NBIX's price/sales ratio has moved down 53.7 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

Stock Date P/S P/B P/E EV/EBIT
NBIX 2021-08-31 8.7 7.0 24.7 92.4
NBIX 2021-08-30 8.8 7.1 24.9 93.2
NBIX 2021-08-27 8.7 7.0 24.7 92.5
NBIX 2021-08-26 8.6 6.9 24.2 90.6
NBIX 2021-08-25 8.7 7.0 24.6 92.0
NBIX 2021-08-24 8.5 6.9 24.1 90.0

NBIX Growth Metrics

    The 5 year price growth rate now stands at 142.63%.
  • Its year over year price growth rate is now at -11.48%.
  • Its year over year cash and equivalents growth rate is now at 87.07%.
Over the past 52 months, NBIX's revenue has gone up $1,066,391,000.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,133.5 256.5 89.6
2021-09-30 1,069.4 341.2 444.8
2021-06-30 1,031.9 261.9 364.7
2021-03-31 1,045.4 277.6 402
2020-12-31 1,045.9 228.5 407.3
2020-09-30 1,042.01 242.153 93.4

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
  • NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
  • LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.566 0.988 0.102
2021-06-30 0.586 0.989 0.063
2021-03-31 0.634 0.990 0.092
2020-12-31 0.684 0.990 0.105
2020-09-30 0.733 0.991 0.118
2020-06-30 0.750 0.991 0.199

NBIX Price Target

For more insight on analysts targets of NBIX, see our NBIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $122.19 Average Broker Recommendation 1.52 (Moderate Buy)

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $98.24 52-week high $108.01
Prev. close $97.40 52-week low $71.88
Day low $95.81 Volume 844,800
Day high $99.05 Avg. volume 812,704
50-day MA $90.92 Dividend yield N/A
200-day MA $89.99 Market Cap 9.39B

Neurocrine Biosciences, Inc. (NBIX) Company Bio

Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.

NBIX Latest News Stream

Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream

Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Neurocrine (NBIX) Receives a Buy from Robert W. Baird

In a report issued on February 11, Brian Skorney from Robert W. Baird maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $117.00. The company's shares closed last Tuesday at $87.56. According to, Skorney is ranked 0 out of 5 stars with an average return of -5.6% and a 43.0% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals. Neurocrine has an analyst consensus of Moderate Buy, with a price target consensus of $115.07, which is a 33.0% upside from current levels. In a report released yesterday, H.C.

Christine Brown on TipRanks | February 15, 2022

Needham Maintains Their Hold Rating on Neurocrine (NBIX)

Needham analyst Ami Fadia maintained a Hold rating on Neurocrine (NBIX – Research Report) today. The company's shares closed last Thursday at $79.60, close to its 52-week low of $71.88. According to, Fadia is a 1-star analyst with an average return of -1.6% and a 45.4% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $114.75 average price target.

Christine Brown on TipRanks | February 11, 2022

Neurocrine (NBIX) Receives a Hold from Mizuho Securities

Mizuho Securities analyst Vamil Divan maintained a Hold rating on Neurocrine (NBIX – Research Report) today and set a price target of $95.00. The company's shares closed last Friday at $85.53. According to, Divan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.7% and a 46.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals. Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $116.43, which is a 44.8% upside from current levels.

Christine Brown on TipRanks | February 11, 2022

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

INGREZZA® (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA® (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $1.35 Billion Expanded Pipeline Expected to Deliver Multiple Registrational and Phase 2 Study Data Readouts Over the Next Two Years SAN DIEGO , Feb.

Neurocrine Biosciences | February 11, 2022

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: Full story available on

Benzinga | February 11, 2022

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo 5.52%
3-mo 5.79%
6-mo 16.61%
1-year -2.04%
3-year 16.36%
5-year 110.05%
YTD 15.35%
2021 -11.14%
2020 -10.83%
2019 50.53%
2018 -7.96%
2017 100.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.597 seconds.